Therapeutic effect of teduglutide on non-alcoholic fatty liver disease in rats

Hu, Yin-Xia; Lan, Li; Yuan, Yu; Wu, Li‐Hao; He, Xiaofu

doi:10.11569/wcjd.v24.i7.1009

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the wake of inspecting the full text, 22 RCTs with 1366 participants were included. The characteristics of the included RCTs studies [ 3 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ] are listed in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis

Lee

Yang

et al. 2020

Nutrients

View full text Add to dashboard Cite

(1) Aim: Non-alcoholic fatty liver disease (NAFLD) is a prevalent disease worldwide. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) bear anti-inflammatory action and can ameliorate hyperlipidemia. We wish to appraise the effects of n-3 PUFAs supplement on NAFLD. (2) Methods: We searched CENTRAL, Embase, and MEDLINE on 29 March 2020 for randomized control trials (RCTs) on the effects of n-3 PUFAs supplementation in treating NAFLD. The Cochrane Collaboration’s tool was used to assess the risk of bias of included RCTs. (3) Results: We included 22 RCTs with 1366 participants. The risk of bias of included RCTs was generally low or unclear. n-3 PUFAs supplementation significantly reduced liver fat compared with placebo (pooled risk ratio 1.52; 95% confidence interval (CI) 1.09 to 2.13). n-3 PUFAs supplementation also significantly improved the levels of triglyceride, total cholesterol, high-density lipoprotein, and body-mass index, with pooled mean difference and 95% CI being −28.57 (−40.81 to −16.33), −7.82 (−14.86 to −0.79), 3.55 (1.38 to 5.73), and −0.46 (−0.84 to −0.08), respectively. (4) Conclusions: The current evidence supports the effects of n-3 PUFAs supplementation in improving fatty liver. n-3 PUFAs supplementation may also improve blood lipid levels and obesity.

show abstract

Section: Resultsmentioning

confidence: 99%

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis

Lee

Yang

et al. 2020

Nutrients

View full text Add to dashboard Cite

show abstract

“…The 5 studies [ 43 – 47 ] excluded from our analysis for being non-RCTs have been included in other meta-analysis; meanwhile, we included the 7 most recent RCTs published in the past 3 years. [ 20 , 21 , 28 , 30 , 34 , 35 ] The previous reviews involved 9, 7, and 10 trials, respectively, which were all published in English; however, we included in our study eighteen RCTs published in both English and languages other than English; 2 previous studies [ 13 , 42 ] assessed the risk of bias using the Jadad score; here, we used the Cochrane risk of bias tool.…”

Section: Discussionmentioning

confidence: 99%

Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…GLP2, usually not considered an incretin, is prevalent in the gastrointestinal tract, where it promotes lipid absorption, regulates intestinal motility, mucosal morphology, function and integrity of the intestine [ 132 ]. Teduglutide, a selective GLP2R agonist, reduced liver steatosis and disease activity scores in rats, possibly by restoring normal intestinal permeability [ 133 ].…”

Section: Glucose Metabolism Modulatorsmentioning

confidence: 99%

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

2022

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the increasingly high medical and socioeconomic burden of NAFLD, the lack of approved pharmacotherapy regimens remains an unsolved issue. In this paper, we aimed to provide an update on the rapidly changing therapeutic landscape and highlight the major novel approaches to the treatment of this disease. In addition to describing the biomolecules and pathways identified as upcoming pharmacological targets for NAFLD, we reviewed the current status of drug discovery and development pipeline with a special focus on recent evidence from clinical trials.

show abstract

Therapeutic effect of teduglutide on non-alcoholic fatty liver disease in rats

Cited by 3 publications

References 0 publications

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis

Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Contact Info

Product

Resources

About